# US 2017/0363650 A1 · Method for determining the fibrinogen concentration in a biological sample

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0363650 A1
- Document ID: US20170363650A1
- Status: Published application
- Kind: A1
- Application number: 15/536,307
- Filed: 2015-12-18
- Published: 2017-12-21
- Earliest claimed: 2014-12-18
- Assignees: Koninklijke Philips N.V.
- Applicants: Koninklijke Philips N.V.
- Inventors: Hendrik JAN VAN OOIJEN; BART JACOB BAKKER; RENÉ VAN DEN HAM
- Web page: https://patentgrep.com/patent/US20170363650A1

## CPC

- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 2333/75: Fibrin; Fibrinogen
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to clinical decision support systems. In detail, the present invention relates to a method for determining the initial fibrinogen concentration in a biological sample, to the use of fibrinogen added to a biological sample in at least one predetermined concentration, to a device for determining the initial fibrinogen concentration in a biological sample, to a computer program comprising program code means for causing a computer to carry out at least several steps of the method according to the invention, to a computer readable non-transitory storage medium containing instructions for carrying out at least some steps of the method according to the invention, and to a kit for determining the initial fibrinogen concentration in a biological sample.

## Claims

### Claim 1

Method for determining the initial fibrinogen concentration in a biological sample comprising the following steps:
providing a biological sample;
adding fibrinogen to said biological sample in at least one predetermined concentration;
starting a clotting process in said biological sample;
determining the attenuance of the biological sample as a function of time to obtain an attenuance curve;
extracting feature values indicative of the fibrinogen concentration in said biological sample from said attenuance curve and recording them as a function of fibrinogen added in step;
calculating a fitted function through said recorded feature values of step;
determining the initial fibrinogen concentration in said biological sample from said fitted function of step.

### Claim 2 (depends on 1)

The method of claim 1, characterized in that said step is realized by the following steps:
extrapolating said fitted function of step to the value of added fibrinogen where said feature value is zero to obtain an extrapolated value;
and/or
extrapolating said fitted function of step to the value of added fibrinogen to a value that coincides with a hypothetical sample with a fibrinogen level of zero to obtain an extrapolated value;
determining the initial fibrinogen concentration in said biological sample by multiplying said extrapolated value by −1.

### Claim 3 (depends on 1)

The method of claim 1, characterized in that said feature values indicative of the fibrinogen concentration in said biological sample are selected from:
difference in attenuance of said biological sample between a first point in time and a second point in time (Δ attenuance), preferably at the starting point of the clotting process as the first point in time, and at the end of the clotting process as the second point in time (Δ attenuance);
maximum attenuance rate (time derivative of attenuance curve);
features which correspond with time, including: lag time, time to (a certain degree of) maximum attenuance.

### Claim 4 (depends on 1)

Method of claim 1, characterized in that said fitted function of step is selected from the group consisting of:
a linear function;
a non-linear function, including: exponential function, power function, reciprocal function.

### Claim 5 (depends on 1)

Method of claim 1, characterized in that in step said clotting process is started by adding a clotting trigger to said biological sample, preferably selected from the group consisting of:
active coagulation factors, including: thrombin (F2a), tissue factor (TF), active FX (FXa), active proconvertin (FVIIa);
snake venom thrombin-like enzymes, including: batroxobin and reptilase;
kaolinite, micronized silica, ellagic acid,
wherein preferably said clotting trigger is added to said biological sample in a concentration sufficiently high that the shape of the attenuance curve is essentially determined by the fibrinogen concentration in the biological sample.

### Claim 6 (depends on 1)

Method of claim 1, characterized in that in step said biological sample is provided in at least two aliquots allowing the execution of steps in said at least two aliquots, preferably in parallel, resulting in the obtainment of at least two attenuance curves.

### Claim 7

Use of fibrinogen added to a biological sample in at least one predetermined concentration for determining the initial fibrinogen concentration in said biological sample.

### Claim 8

A device for determining the initial fibrinogen concentration in a biological sample comprising:
a container capable of receiving a biological sample and an addition of fibrinogen in at least one predetermined concentration;
a measuring unit configured for measuring the attenuance of said biological sample;
a calculating unit configured for:
determining the attenuance of the biological sample as a function of time to obtain an attenuance curve;
extracting feature values indicative of the fibrinogen concentration in said biological sample from said attenuance curve and recording them as a function of fibrinogen to said biological sample;
calculating a fitted function through said recorded feature values;
determining the initial fibrinogen concentration in said biological sample from said fitted function.

### Claim 9 (depends on 8)

The device of claim 8, characterized in that said calculating unit is further configured for:
extrapolating said fitted function to the value of added fibrinogen where said feature value is zero to obtain an extrapolated value and/or
extrapolating said fitted function to the value of added fibrinogen to a value that coincides with a hypothetical sample with a fibrinogen level of zero to obtain an extrapolated value;
determining the initial fibrinogen concentration in said biological sample by multiplying said extrapolated value by −1.

### Claim 10 (depends on 8)

The device of claim 8, characterized in that said container is a multi-well container capable for receiving at least two aliquots of said biological sample, preferably a microtiter plate or a cartridge with multiple fluid chambers.

### Claim 11 (depends on 8)

The device of claim 8, characterized in that said measuring unit is an optical measuring system comprising at least one light source and at least one light detector.

### Claim 12 (depends on 8)

The device of claim 8, characterized in that said calculating unit comprises a processor and a computer-readable storage medium, wherein said computer-readable storage medium contains instructions for execution by said processor, wherein preferably said instructions cause said processor to perform the steps of:
determining the attenuance of the biological sample as a function of time to obtain an attenuance curve;
extracting feature values indicative of the fibrinogen concentration in said biological sample from said attenuance curve and recording them as a function of fibrinogen to said biological sample;
calculating a fitted function through said recorded feature values;
determining the initial fibrinogen concentration in said biological sample from said fitted function,
and preferably
extrapolating said fitted function to the value of added fibrinogen where said feature value is zero to obtain an extrapolated value
and/or
extrapolating said fitted function to the value of added fibrinogen to a value that coincides with a hypothetical sample with a fibrinogen level of zero to obtain an extrapolated value;
determining the initial fibrinogen concentration in said biological sample by multiplying said extrapolated value by −1.

### Claim 13 (depends on 1)

Computer program comprising program code means for causing a computer to carry out at least the steps, and of the method of claim 1 when said computer program is carried out on the computer.

### Claim 14 (depends on 1)

A computer-readable non-transitory storage medium containing instructions for execution by a processor, wherein the instructions cause the processor to carry out at least the steps, and of the method of claim 1.

### Claim 15 (depends on 1)

A kit for determining the initial fibrinogen concentration in a biological sample comprising:
the device and;
fibrinogen, preferably in solution comprising a predetermined concentration thereof;
a manual for performing the method of claim 1;
optionally
a clotting trigger, preferably selected from the group consisting of:
active coagulation factors, including: thrombin (F2a), tissue factor (TF), active FX (FXa), active proconvertin (FVIIa);
snake venom thrombin-like enzymes, including: batroxobin and reptilase;
kaolinite;
further optionally
